Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies
|
|
- Bethany Blair
- 6 years ago
- Views:
Transcription
1 Therapeutic Advances in Chronic Disease Review Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies Ther Adv Chronic Dis (2010) 1(3) DOI: / ! The Author(s), Reprints and permissions: journalspermissions.nav Fernando Bermejo and Javier P. Gisbert Abstract: 5-aminosalicylic acid (5-ASA) and thiopurines (azathioprine and mercaptopurine) are the most common drugs used as a maintenance treatment for ulcerative colitis. A considerable proportion of these patients develop corticosteroid dependency, and thiopurines are the standard treatment in this scenario. Dual prescriptions of both thiopurines and 5-ASA are common practice in steroid-dependent ulcerative colitis, in an attempt to optimize the efficacy of therapy. On the one hand, the potential protective role of 5-ASA against colorectal cancer argues in favour of prescription of both medications. The possible synergism between the two drugs, because of the inhibition of thiopurine methyltransferase (TPMT) enzyme activity by 5-ASA, has been postulated as another justification for dual prescription. However, existing evidence does not support that this combined strategy is superior to monotherapy with thiopurines. On the other hand, in patients showing prolonged disease remission, the possibility of discontinuing maintenance treatment can be considered on an individualized basis. The high frequency of relapses after thiopurine withdrawal should always be taken into account, but the potential adverse effects of the medication also need to be considered. A properly indicated treatment with thiopurines may need to be continued for life in many patients. Keywords: azathioprine, mercaptopurine, mesalazine, salicylate, thiopurine, ulcerative colitis Introduction Ulcerative colitis (UC) is an inflammatory bowel disease characterized by the alternation of symptomatic periods and periods of disease remission. After achieving remission of a flare up as a result of medical treatment, the objective is to prevent UC relapse. Various potentially useful drugs are available for this purpose, and the choice depends on the characteristics of the disease: its extent, flare-up response to treatment, and the behaviour after corticosteroid withdrawal, with the possible appearance of corticosteroid dependency. The drugs used as maintenance treatment for UC are fundamentally 5-aminosalicylic acid (5-ASA) and the thiopurinic immunosuppressors [Sands, 2006; Sutherland and MacDonald, 2006; Hanauer, 2004]. For over 50 years, 5-ASA, sulfasalazine and mesalazine have been the drugs most widely used to treat UC, starting with the introduction of sulfasalazine by Svartz in 1942 [Svartz, 1942], and these are the substances normally used as maintenance therapy in patients with UC [Travis et al. 2008; Sutherland and MacDonald, 2006; Gisbert et al. 2002]. The thiopurines, azathioprine (AZA) and mercaptopurine (MP), represent the treatment of choice in UC patients who develop corticosteroid dependency [Stange et al. 2008], and these drugs offer high efficacy in this clinical scenario [Gisbert et al. 2009; Travis et al. 2008; Ardizzone et al. 2006; Ghosh et al. 2006; Sands, 2006; Lopez-Sanroman et al. 2004; Fraser et al. 2002]. A considerable proportion of patients who develop corticosteroid dependency have previously been subjected to maintenance therapy with salicylates. When the course of the disease requires taking a further step up the therapeutic ladder with the administration of thiopurines, doubts may arise as to whether or not 5-ASA should be maintained. Even in the absence of 5-ASA therapy, the question may arise as to whether it is worth adding the latter to AZA/MP treatment, in an attempt to optimize UC therapy. The metabolism of AZA/MP is well known, and involves a series of enzyme reactions Correspondence to: Fernando Bermejo, MD, PhD Department of Gastroenterology, Hospital Universitario de Fuenlabrada, Ríos Rosas 17, Madrid, Spain fbermejos@medynet.com Javier P. Gisbert, MD, PhD Hospital Universitario de La Princesa and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain 107
2 Therapeutic Advances in Chronic Disease 1 (3) with methylation by thiopurine methyltransferase (TPMT), oxidation mediated by xanthine oxidase to yield thiouric acid, or catabolism through the mediation of hypoxanthine guanine phosphoribosyl transferase, which leads to the production of 6-thioguanine nucleotides, which are fundamentally responsible for the activity of these drug substances. One of the most widely studied of these implicated enzymes is TPMT [Gisbert et al. 2007a], the activity of which is influenced by both genetic polymorphisms and different drugs, possibly including 5-ASA. In view of the above considerations, a review is made of the existing evidence on the usefulness of thiopurine and 5-ASA coprescription. On the other hand, in patients with steroiddependent UC showing prolonged remission, the doubt may arise in both the patient and prescribing physician as to whether treatment can be suspended in view of the stability of the disease. However, in order to be able to make a decision, due evaluation is required of the potential risks and benefits of suspending treatment. On the one hand, suspension can give rise to undertreated disease and the risk of reactivation, while on the other hand the indefinite maintenance of treatment increases the possibility of drug adverse effects [de Jong et al. 2003]. The present study thus reviews the existing evidence to help take decisions in this clinical scenario. Frequency of thiopurine and 5-ASA coprescription, and its bases In some series, the frequency of AZA and 5-ASA coprescription in patients with steroid-dependent UC exceeds 70% [Actis et al. 2009]. In a survey conducted in the United Kingdom involving 97 gastroenterologists (38% response rate with respect to the total physicians surveyed), 79% of those interviewed claimed to apply coprescription. In addition, 20% of their UC patients received combined treatment with AZA and 5-ASA, and 94% of the physicians recommended life-long 5-ASA use [Mayberry et al. 2009]. The possible existence of synergism between the two drug substances, as a result of the inhibition of TPMT enzyme activity by 5-ASA, described in in vitro studies [Xin et al. 2005; Szumlanski and Weinshilboum, 1995], has been postulated as a justification of coprescription. The mentioned enzyme is of particular interest, owing to its intervention in several steps of thiopurine metabolism. In this context, it has been suggested that in patients with high TPMT enzyme levels (i.e. hypermethylators), the administration of 5-ASA may help to optimize thiopurine efficacy by directing metabolism of the drug towards the production of 6-thioguanine nucleotides (active thiopurine metabolites), and avoiding the accumulation of potentially hepatotoxic methylated derivatives [Lowry et al. 2001]. However, a considerable number of in vivo studies have been unable to demonstrate significant changes in TPMT levels associated with 5-ASA therapy [Lowry et al. 2001] or with the discontinuation of such therapy [Dewit et al. 2002]. Xin and colleagues have reported that of the different 5-ASA drugs, only sulfasalazine exhibits in vivo TPMT inhibiting potential, although the authors did not analyse the impact of this fact upon treatment efficacy [Xin et al. 2005]. The technical procedure used to measure erythrocyte TPMT activity could explain the absence of changes in TPMT activity with 5-ASA use reported by in vivo studies. In effect, during preparation of the erythrocyte lysates, all metabolites are washed out. Accordingly, if 5-ASA metabolites are removed during TPMT analysis, this might lead to normalization of inhibition of TPMT activity [Gilissen et al. 2005]. In a recent study comparing a group of patients receiving cotreatment versus another administered AZA monotherapy, Daperno and colleagues observed no differences in TPMT activity between the two groups, and no relationship was found between the 5-ASA dose used and TPMT activity. Likewise, no differences were found in 6-thioguanine and 6-methylmercaptopurine levels between the two patient groups [Daperno et al. 2009]. These results differ from those recorded in other intervention studies in which the addition of 5-ASA to stable thiopurine doses was found to significantly increase the 6-thioguanine levels [de Boer et al. 2007; Gilissen et al. 2005]. Daperno and colleagues postulated that after early interference, adaptation occurs, leading to minor interference between the two drugs [Daperno et al. 2009]. This hypothesis would be supported by the findings of a study in patients with surgically treated Crohn s disease, in which both AZA and mesalazine did not alter the TPMT levels after 1 year of treatment [Dilger et al. 2007]. Lastly, it could be speculated that the interaction between 5-ASA and thiopurines would have a 108
3 F Bermejo and JP Gisbert greater potential impact upon patients with low TPMT activity, increasing the risk of bone marrow toxicity, although this would have to be confirmed by adequately designed prospective studies. Efficacy of thiopurine and 5-ASA coprescription The interaction between 5-ASA and thiopurines could have an influence on the management of patients with inflammatory bowel disease in a number of aspects: AZA/MP dose, efficacy and potential adverse effects. There are contradictory data and opinions on the possible usefulness of coprescription. Some investigators suggest that coprescription is useful and increases the efficacy of AZA/MP and the levels of 6-thioguanine nucleotides (active thiopurine metabolites) [Stocco et al. 2008; de Boer et al. 2007; Hande et al. 2006; Dewit et al. 2002]. On the other hand, the use of 5-ASA as colon cancer chemoprophylaxis would be another element in favour of coprescription in patients with steroid-dependent UC [Rubin et al. 2008; Van Staa et al. 2005; Velayos et al. 2005]. Patients with long-evolving UC are at greater risk of developing colon cancer than the general population, with a prevalence of 3.7% [Eaden et al. 2001]. 5-ASA treatment appears to reduce this risk by 40 75%, with a number needed to treat (NNT) of 7 patients after 30 years [Van Staa et al. 2005; Eaden et al. 2000]. Daily sulfasalazine doses of over 2 g, or mesalazine doses above 1.2 g, appear to offer increased preventive benefit [Velayos et al. 2005]. The chemoprophylactic action of 5-ASA appears to be dependent upon binding of the drug to a potent colonocyte differentiating factor [Dubuquoy et al. 2006]. This potential beneficial effect of 5-ASA in reducing colon cancer risk at an acceptable cost could be important in justifying the administration of maintenance therapy for years, apart from the inherent therapeutic effect obtained in terms of the prevention of disease relapse, and would support 5- ASA and AZA/MP coprescription [Andrews et al. 2009]. In contrast, other authors have reported that the addition of 5-ASA does not increase the efficacy of AZA/MP in steroid-dependent UC. Indeed, it may even increase toxicity, by directing drug metabolism towards the production of 6-thioguanine nucleotides, thus increasing the risk of bone marrow toxicity [Lowry et al. 2001] and the likeliness of having to suspend AZA/MP, which is the main source of therapeutic effects in patients with steroid-dependent UC. In this sense, Shah and colleagues have described the appearance of more adverse effects in patients subjected to coprescription than in those administered thiopurine monotherapy [Shah et al. 2008]. On the other hand, the fact of administering a larger number of drugs in the context of prolonged maintenance therapy could adversely affect patient adherence, this being a key factor for the success of a chronic disorder such as UC [Kane, 2006; López San Román et al. 2005; Kane et al. 2003]. A recent systematic review of the efficacy of thiopurine and 5-ASA coprescription in UC concluded that the existing evidence obtained from clinical trials is insufficient to demonstrate whether simultaneous AZA and 5-ASA therapy improves the results of AZA in monotherapy [Andrews et al. 2009]. The conclusions of the mentioned review point to AZA and 5-ASA as compatible treatments without a significant increase in adverse effects, although monitoring of the possible development of bone marrow toxicity is recommended if 5-ASA is added to treatment, or if the dose of this drug is increased [Andrews et al. 2009]. In this context, the guidelines of the European Crohn s and Colitis Organization (ECCO), in the section on thiopurine treatment for UC, indicate that the addition or maintenance of oral mesalazine can be recommended, with special monitoring of possible marrow toxicity, although this recommendation is based on low levels of evidence (level of evidence 5, degree of recommendation D) [Travis et al. 2008]. What happens on suspending AZA/MP in remitting steroid-dependent UC? UC patients receiving treatment with AZA/MP often ask for how long such treatment is needed. Can the medication be suspended at some point? No definitive answer to this question can be offered. The ECCO guidelines on UC [Travis et al. 2008] regarding the duration of thiopurine treatment indicate that because of the lack of evidence, no recommendation can be made, although the prolonged use of these drugs can be considered if necessary (level of evidence 4, degree of recommendation D). A recent multicentre retrospective study offers interesting information for attempting to offer answers to our patients [Cassinotti et al. 2009]
4 Therapeutic Advances in Chronic Disease 1 (3) In the mentioned study, Cassinotti and colleagues presented a series of 127 patients in which treatment was suspended upon decision by either the patient or the physician (3/4 of all cases), or as a result of intolerance. Approximately 75% of the subjects had been in disease remission without flare ups, while the rest had shown some degree of activity during treatment with AZA. As an interesting observation related the previous section of our study, the authors found cotreatment with 5-ASA to be the only predictor of sustained disease remission during treatment with AZA. Following AZA suspension, 5-ASA was prescribed in most of the patients, although 21% were left without maintenance therapy. Clinical relapse during follow up was both frequent and early: in one third of the patients after 12 months, one half after 2 years, and in two thirds after 5 years [Cassinotti et al. 2009], these figures being globally similar to those reported for Crohn s disease [Treton et al. 2009]. The relapse-predicting factors after AZA suspension were: (1) treatment duration, with less-frequent relapses among subjects who had received therapy for over 2 years; (2) sustained remission during treatment, with a 59% relapse rate among patients showing sustained remission, versus 91% in those who had not achieved sustained remission; and (3) the extent of UC, with an increased relapse risk in extensive disease than in patients with left colitis. However, the possible influence of the extent of the disease must be viewed with caution, since approximately one half of all UC patients experience changes in disease extent over time [Farmer et al. 1993]. In the study published by Cassinotti and colleagues, colectomy was required in up to 10% of the patients (4% after 1 year and 9% after 3 years) in which AZA was suspended, such surgery in turn involving a nonnegligible degree of morbidity mortality [Cassinotti et al. 2009]. Although the global data are similar to those published by Treton and colleagues in luminal Crohn s disease [Treton et al. 2009], on analysing the specific data corresponding to the patients with a favourable course and who remained in remission during treatment with AZA, it was seen that AZA suspension could be decided with good results in up to two thirds of the patients with Crohn s disease versus only one third of the patients with UC. Therefore, it seems that AZA suspension implies a poorer course in UC than in Crohn s disease. The only randomized trial on AZA withdrawal in 79 patients with steroid-dependent UC involving a follow up of 1 year reported a 36% relapse rate in the group maintaining active treatment (AZA), versus 59% in the placebo group (p ¼ 0.03). The differences were evident on analysing the subgroup of patients with prolonged disease remission (31% versus 61%; p < 0.01) [Hawthorne et al. 1992]. Likewise, data are available on the experience of a single centre over a period of 30 years in 222 patients, although this series combines patients with UC and Crohn s disease. In this study, the relapse rate was 37% after 1 year, 54% after 2 years, and 75% after 5 years,with no influence on the part of the duration of AZA therapy [Fraser et al. 2002]. A European multicentre but retrospective study offers interesting information, considering the large number of patients involved: 818 patients with Crohn s disease and 358 with UC. The patients were stratified according to the duration of AZA therapy (less than 3 years, 3 4 years and over 4 years). The reasons for suspending AZA were physician decision (50%), patient decision (25%) and toxicity or other reasons in the rest of the cases. The results, and thus the recommendations of the authors, differed for Crohn s disease and UC [Holtmann et al. 2006]. In the case of Crohn s disease, AZA suspension after 3 4 years did not lead to disease reactivation or to an increase in corticosteroid requirements, although when therapy was prolonged for over 4 years a significant decrease was noted in the number of flare ups and in corticosteroid requirements. As a result, in asymptomatic patients with Crohn s disease with no need for corticosteroid therapy after 3 4 years of AZA treatment, the authors suggested that the latter medication could be suspended, while in patients with clinical disease activity or who required corticosteroids at some point during treatment with AZA, the latter should be maintained. In contrast, in patients with UC, treatment for over 4 years significantly reduced the corticosteroid requirements and number of flare ups, and when AZA was suspended, the observed tendency was towards an increase in flare ups and corticosteroid use. The authors therefore considered it to be of benefit to continue AZA for more than 4 years in UC patients [Holtmann et al. 2006]. Undoubtedly, the high frequency of relapses after AZA/MP suspension must be taken into account by both the patient and the supervising physician, before taking the decision to suspend an effective treatment. On the downside, we have the 110
5 F Bermejo and JP Gisbert potential adverse effects of the thiopurines, which are seen in approximately 20% of all cases [de Jong et al. 2003; Bowen and Selby, 2000], and which lead to treatment suspension in about 10% of all cases [Gisbert et al. 2007c; Lichtenstein et al. 2006]. Some of these adverse effects, such as bone marrow toxicity and liver toxicity, can manifest even years after the start of treatment [Gisbert and Gomollon, 2008; Gisbert et al. 2007b]. Another important aspect is a certain increase in the risk of developing lymphoproliferative disorders, described by a number of investigators [Kandiel et al. 2005], although globally the absolute risk is low. All of these factors should be taken into consideration when pondering the suspension of thiopurine therapy in patients with long-remitting UC. What is the effect of suspending the aminosalicylate in steroid-dependent UC subjected to AZA/MP and 5-ASA coprescription? 5-ASA suspension in patients subjected to combined treatment with this drug and AZA/MP may give rise to a drop in 6-thioguanine levels [Gilissen et al. 2005; Dewit et al. 2002], although the true effect of such variations in thiopurine metabolite levels upon the clinical efficacy of these drug substances is not known. There have been isolated reports of patients subjected to coprescription in which the suspension of mesalazine was accompanied by UC relapse despite treatment with AZA [Actis et al. 2008; Stocco et al. 2008]. As a result, monitoring of possible relapse has been recommended if the decision is taken to suspend 5-ASA in UC patients subjected to coprescription [Andrews et al. 2009], although the supporting evidence is very limited. On the other hand, on examining the advantages and risks of 5-ASA suspension, it must be remembered that discontinuation of the drug could lead to a loss of the protective effect of these drugs against colorectal cancer in UC patients [Rubin et al. 2008; Van Staa et al. 2005; Velayos et al. 2005]. In turn, however, such a measure could improve adherence to therapy, since the patient would be required to take fewer drugs and fewer tablets each day [Kane, 2006]. Some authors have suggested the possibility of suspending salicylate treatment in UC if the patient has been free of symptoms for a long period of time and is found to be in clinical, histological and endoscopic disease remission [Ardizzone et al. 1999]. Other experts and clinical guides recommend long-term maintenance therapy with 5-ASA in order to secure optimum treatment results, based on the efficacy of such drugs in reducing the risk of colorectal cancer [Travis et al. 2008; Sandborn, 2006; Carter et al. 2004]. Nevertheless, the lack of conclusive data from clinical trials makes it necessary to establish this decision on an individualized basis according to the characteristics of the patient and the disease. Thus, in the context of steroiddependent UC, in coprescribed patients and on contemplating suspension of some of the drugs in response to patient request or with the purpose of improving adherence to therapy, we could consider withdrawing 5-ASA and maintaining AZA/MP, since the latter represents the active treatment reverting the situation of corticosteroid dependency. Conclusions The coprescription of thiopurines and 5-ASA is common practice in patients with steroid-dependent UC, although the existing evidence does not allow us to confirm that this strategy is superior to monotherapy with AZA/MP. The potential protective role of 5-ASA against colorectal cancer argues in favour of coprescription. However, the associated increase in the number of drugs administered as long-term maintenance therapy can worsen patient adherence: good adherence is a key factor for the success of treatment. In patients showing prolonged disease remission as confirmed by the clinical, endoscopic and histological findings, the possibility of suspending maintenance treatment may be considered. Such a decision must be established on an individualized basis according to the characteristics of the patient (initial indication, adherence to therapy), the disease (severity and previous course) and patient opinion. In this context, the patient must be made aware not only of the high probability of disease relapse if AZA/MP is suspended in the context of steroid-dependent UC, but also of the potential adverse effects of the medication. However, if thiopurine treatment was well indicated, it may have to be continued for life. Conflict of interest statement The authors declare no conflicts of interest in preparing this manuscript
6 Therapeutic Advances in Chronic Disease 1 (3) References Actis, G.C., Marzano, A., Pellicano, R. and Rizzetto, M. (2008) How important is mesalamine in the maintenance of steroidrefractory colitis? Inflamm Bowel Dis 14: Actis, G.C., Pellicano, R., Rizzetto, M., Ayoubi, M., Leone, N., Tappero, G. et al. (2009) Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease. World J Gastroenterol 15: Andrews, J.M., Travis, S.P., Gibson, P.R. and Gasche, C. (2009) Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Ailment Pharmacol Ther 29: Ardizzone, S., Maconi, G., Russo, A., Imbesi, V., Colombo, E. and Bianchi Porro, G. (2006) Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55: Ardizzone, S., Petrillo, M., Imbesi, V., Cerutti, R., Bollani, S. and Bianchi Porro, G. (1999) Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Ailment Pharmacol Ther 13: Bowen, D.G. and Selby, W.S. (2000) Use of 6-mercaptopurine in patients with inflammatory bowel disease previously intolerant of azathioprine. Dig Dis Sci 45: Carter, M.J., Lobo, A.J. and Travis, S.P.; IBD Section, British Society of Gastroenterology (2004) Guidelines for the management of inflammatory bowel disease in adults. Gut 53(Suppl 5): V1 V16. Cassinotti, A., Actis, G.C., Duca, P., Massari, A., Colombo, E., Gai, E. et al. (2009) Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 104: Daperno, M., Sostegni, R., Canaparo, R., Serpe, L., Lavagna, A., Crocellà, L. et al. (2009) Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease. Ailment Pharmacol Ther 30: de Boer, N.K., Wong, D.R., Jharap, B., de Graaf, P., Hooymans, P.M., Mulder, C.J. et al. (2007) Dosedependent influence of 5-aminosalicylates on thiopurine metabolism. Am J Gastroenterol 102: de Jong, D.J., Derijks, L.J., Naber, A.H., Hooymans, P.M. and Mulder, C.J. (2003) Safety of thiopurines in the treatment of inflammatory bowel disease. Scand J Gastroenterol Suppl 2003: Dewit, O., Vanheuverzwyn, R., Desager, J.P. and Horsmans, Y. (2002) Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn s disease. Ailment Pharmacol Ther 16: Dilger, K., Schaeffeler, E., Lukas, M., Strauch, U., Herfarth, H., Müller, R. et al. (2007) Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn s disease during 1 year of treatment with azathioprine or mesalazine. Ther Drug Monit 29: 1 5. Dubuquoy, L., Rousseaux, C., Thuru, X., Peyrin-Biroulet, L., Romano, O., Chavatte, P. et al. (2006) PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut 55: Eaden, J., Abrams, K., Ekbom, A., Jackson, E. and Mayberry, J. (2000) Colorectal cancer prevention in ulcerative colitis: a case control study. Ailment Pharmacol Ther 14: Eaden, J.A., Abrams, K.R. and Mayberry, J.F. (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48: Farmer, G.R., Easley, K.A. and Rankin, G.B. (1993) Clinical patterns, natural history and progression of ulcerative colitis. Dig Dis Sci 38: Fraser, A.G., Orchard, T.R. and Jewell, D.P. (2002) The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50: Ghosh, S., Chaudhary, R., Carpani, M. and Playford, R.J. (2006) Is thiopurine therapy in ulcerative colitis as effective as in Crohn s disease? Gut 55: 6 8. Gilissen, L.P., Bierau, J., Derijks, L.J., Bos, L.P., Hooymans, P.M., van Gennip, A. et al. (2005) The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients. Ailment Pharmacol Ther 22: Gisbert, J.P., Gomollón, F., Cara, C., Luna, M., González-Lama, Y., Pajares, J.M. et al. (2007a) Thiopurine methyltransferase activity in Spain: a study of 14,545 patients. Dig Dis Sci 52: Gisbert, J.P., Gomollon, F., Mate, J. and Pajares, J.M. (2002) Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci 47: Gisbert, J.P. and Gomollón, F. (2008) Thiopurineinduced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 103: Gisbert, J.P., González-Lama, Y. and Maté, J. (2007b) Thiopurine-induced liver injury in patients with inflammatory bowel disease: a systematic review. Am J Gastroenterol 102: Gisbert, J.P., Linares, P.M., McNicholl, A.G., Mate, J. and Gomollón, F. (2009) Meta-analysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Ailment Pharmacol Ther 30: Gisbert, J.P., Luna, M., González-Lama, Y., Pousa, I.D., Velasco, M., Moreno-Otero, R. et al. (2007c) Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis 13:
7 F Bermejo and JP Gisbert Hanauer, S.B. (2004) Review article: Long-term management of ulcerative colitis. Ailment Pharmacol Ther 20(Suppl 4): Hande, S., Wilson-Rich, N., Bousvaros, A., Zholudev, A., Maurer, R., Banks, P. et al. (2006) 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 12: Hawthorne, A.B., Logan, R.F., Hawkey, C.J., Foster, P.N., Axon, A.T., Swarbrick, E.T. et al. (1992) Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 305: Holtmann, M.H., Krummenauer, F., Claas, C., Kremeyer, K., Lorenz, D., Rainer, O. et al. (2006) Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci 51: Kandiel, A., Fraser, A.G., Korelitz, B.I., Brensinger, C. and Lewis, J.D. (2005) Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 54: Kane, S., Huo, D., Aikens, J. and Hanauer, S. (2003) Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114: Kane, S.V. (2006) Systematic review: adherence issues in the treatment of ulcerative colitis. Ailment Pharmacol Ther 23: Lichtenstein, G.R., Abreu, M.T., Cohen, R. and Tremaine, W. (2006) American Gastroenterological Association Institute technical review on corticosteroids, inmunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130: Lopez-Sanroman, A., Bermejo, F., Carrera, E. and García-Plaza, A. (2004) Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid dependent ulcerative colitis. Ailment Pharmacol Ther 20: López San Román, A., Bermejo, F., Carrera, E., Pérez-Abad, M. and Boixeda, D. (2005) Adherence to treatment in inflammatory bowel disease. Rev Esp Enferm Dig 97: Lowry, P.W., Franklin, C.L., Weaver, A.L., Szumlanski, C.L., Mays, D.C., Loftus, E.V. et al. (2001) Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine or balsalazide. Gut 49: Mayberry, H., Moshkovska, T. and Mayberry, J.F. (2009) Co-prescribing azathiopurine or 6-mercaptopurine and 5-aminosalicylate compounds in ulcerative colitis. Inflamm Bowel Dis 15: Rubin, D.T., Cruz-Correa, M.R., Gasche, C., Jass, J.R., Lichtenstein, G.R., Montgomery, E.A. et al.; 5-ASA in Colorectal Cancer Prevention Meeting Group (2008) Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 14: Sandborn, W.J. (2006) Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev Gastroenterol Dis 6: Sands, B.E. (2006) Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut 55: Shah, J.A., Edwards, C.M. and Probert, C.S. (2008) Should azathioprine and 5-aminosalicylates be coprescribed in inflammatory bowel disease? An audit of adverse events and outcome. Eur J Gastroenterol Hepatol 20: Stange, E.F., Travis, S.P.L., Vermeire, S., Reinisch, W., Geboes, K., Barakauskiene, A. et al. for the European Crohn s and Colitis Organisation (ECCO) (2008) European evidence-based Consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohn s Colitis 2: Stocco, G., Martelossi, S., Malusa, N., Marino, S., Decorti, G., Bartoli, F. et al. (2008) Interruption of mesalamine and reduction of the blood concentration of the active metabolites of azathioprine: possible causes of ulcerative colitis relapse. Dig Dis Sci 53: Sutherland, L. and MacDonald, J.K. (2006) Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev CD Svartz, N. (1942) Salazopyrin, a new sulfanilamide preparation. Acta Medica Scand 110: Szumlanski, C.L. and Weinshilboum, R.M. (1995) Sulphasalazine inhibition of thiopurine methyltransferase: possible mechanism for interaction with 6- mercaptopurine and azathioprine. Br J Clin Pharmacol 39: Travis, S.P.L., Stange, E.F., Lémann, M., Øresland, T., Bemelman, W.A., Chowers, Y. et al. for the European Crohn s and Colitis Organisation (ECCO) (2008) European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn s Colitis 2: Treton, X., Bouhnik, Y., Mary, J.Y., Colombel, J.F., Duclos, B., Soule, J.C. et al. Groupe D Etude Thérapeutique Des Affections Inflammatoires Du Tube Digestif (GETAID) (2009) Azathioprine withdrawal in patients with Crohn s disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol 7: Van Staa, T.P., Card, T., Logan, R.F. and Leufkens, H.G. (2005) 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54:
8 Therapeutic Advances in Chronic Disease 1 (3) Visit SAGE journals online Velayos, F.S., Terdiman, J.P. and Walsh, J.M. (2005) Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 100: Xin, H., Fischer, C., Schwab, M. and Klotz, U. (2005) Effects of aminosalicylates on thiopurine S-methyltransferase activity: an ex vivo study in patients with inflammatory bowel disease. Ailment Pharmacol Ther 21:
Review article: the long-term management of ulcerative colitis
Aliment Pharmacol Ther 2004; 20 (Suppl. 4): 97 101. Review article: the long-term management of ulcerative colitis S. B. HANAUER Section of Gastroenterology, University of Chicago, Chicago, IL, USA SUMMARY
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationP de Graaf 1, NKH de Boer 2, DR Wong 3, S Karner 4, B Jharap 2, PM Hooymans 3, AI Veldkamp 1, CJJ Mulder 2, AA van Bodegraven 2 and M Schwab 4,5
British Journal of Pharmacology (2010), 160, 1083 1091 2010 The Authors Journal compilation 2010 The British Pharmacological Society All rights reserved 0007-1188/10 www.brjpharmacol.org RESEARCH PAPER
More informationMild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested. Philippe Marteau, Paris, France
Mild-moderate Ulcerative Colitis Sequential & Combined treatments need to be tested Philippe Marteau, Paris, France Sequential vs combined treatments When should one switch? Sequential vs combined treatments
More informationOnce Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis
Once Daily Dosing for Induction and Maintenance of Remission in Ulcerative Colitis John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University JKM 2014 Svartz N. Acta Med Scand
More informationCLINICAL TRIAL PROTOCOL
CLINICAL TRIAL PROTOCOL Protocol Title: A randomised, open study of aminosalicylate withdrawal in patients with ulcerative colitis in established remission on combination treatment of azathioprine (or
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community.
More informationOptimizing treatment with thioguanine derivatives in inflammatory bowel disease
Optimizing treatment with thioguanine derivatives in inflammatory bowel disease Edouard Louis MD, PhD Jacques Belaiche MD, PhD Service de Gastroentérologie, CHU de Liège, 4000 Liège, Belgium Abstract Thioguanine
More informationTreatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort
Alimentary Pharmacology and Therapeutics Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort N. Gies, K. I. Kroeker, K. Wong & R. N. Fedorak Division
More informationDENOMINATOR: All patients aged 18 and older with a diagnosis of inflammatory bowel disease
Measure #270: Inflammatory Bowel Disease (IBD): Preventive Care: Corticosteroid Sparing Therapy National Quality Strategy Domain: Effective Clinical Care 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationThiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease
Original article Annals of Gastroenterology (2012) 25, 1-5 Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease Μaria Gazouli
More informationMercaptopurine and inflammatory bowel disease: the other thiopurine
30-008/207/09//0-6 Revista Española de Enfermedades Digestivas Copyright 207. SEPD y ARÁN EDICIONES, S.L. Rev Esp Enferm Dig 207, Vol. 09, N.º, pp. 0-6 ORIGINAL PAPERS Mercaptopurine and inflammatory bowel
More informationReview article: induction therapy for patients with active ulcerative colitis
Alimentary Pharmacology & Therapeutics Review article: induction therapy for patients with active ulcerative colitis S. P. L. TRAVIS John Radcliffe Hospital and Linacre College, Oxford, UK Correspondence
More informationLatest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals
Latest Treatment Updates for Ulcerative Colitis: Evolving Treatment Goals Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationLessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis
Lessons to learn from Crohn's disease clinical trials: implications for ulcerative colitis Aránzazu Jáuregui Amézaga, Elena Ricart, Julián Panés Department of Gastroenterology, Hospital Clínic de Barcelona,
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationAccepted Article. Mercaptopurine and inflammatory bowel disease: the other thiopurine
Accepted Article Mercaptopurine and inflammatory bowel disease: the other thiopurine Fernando Bermejo San José, Alicia Algaba, Sergio López Durán, Iván Guerra, Marta Aicart, María Hernández-Tejero, Elena
More informationAzathioprine treatment during lactation
Alimentary Pharmacology & Therapeutics Azathioprine treatment during lactation L.A.CHRISTENSEN*,J.F.DAHLERUP*,M.J.NIELSEN*,J.F.FALLINGBORG &K.SCHMIEGELOWà *Department of Medicine V, Århus University Hospital,
More informationUlcerative Colitis: Refining our Management and Incorporating Newer Concepts
Ulcerative Colitis: Refining our Management and Incorporating Newer Concepts Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz The Mt. Sinai School of Medicine Refining our Management
More informationPrevalence of Nonadherence With Maintenance Mesalamine in Quiescent Ulcerative Colitis
THE AMERICAN JOURNAL OF GASTROENTEROLOGY Vol. 96, No. 10, 2001 2001 by Am. Coll. of Gastroenterology ISSN 0002-9270/01/$20.00 Published by Elsevier Science Inc. PII S0002-9270(01)03245-2 Prevalence of
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationMEDICAL POLICY SUBJECT: GENOTYPING OR PHENOTYPING FOR THIOPURINE METHYLTRANSFERASE (TPMT) FOR PATIENTS TREATED WITH AZATHIOPRINE (6-MP)
MEDICAL POLICY SUBJECT: GENOTYPING OR PHENOTYPING PAGE: 1 OF: 5 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product (including
More informationFactors that modify therapy adherence in patients with inflammatory bowel disease
Journal of Crohn's and Colitis (2010) 4, 422 426 available at www.sciencedirect.com Factors that modify therapy adherence in patients with inflammatory bowel disease Fernando Bermejo a,, Antonio López-San
More informationIncidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:760 765 Incidence of Colectomy During Long-term Follow-up After Cyclosporine-Induced Remission of Severe Ulcerative Colitis DAVID N. MOSKOVITZ, GERT VAN
More informationResponse to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients
Response to First Intravenous Steroid Therapy Determines the Subsequent Risk of Colectomy in Ulcerative Colitis Patients Tamás Molnár 1, Klaudia Farkas 1, Tibor Nyári 2, Zoltán Szepes 1, Ferenc Nagy 1,
More informationClinical Study Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis
Hindawi Publishing Corporation Gastroenterology Research and Practice Volume 2013, Article ID 192794, 6 pages http://dx.doi.org/10.1155/2013/192794 Clinical Study Clinical Study of the Relation between
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationOutcome Predictors for Thiopurine Maintenance Therapy in Patients with Crohn s Disease
Outcome Predictors for Thiopurine Maintenance Therapy in Patients with Crohn s Disease Jae Jun Park Department of Medicine The Graduate School, Yonsei University Outcome Predictors for Thiopurine Maintenance
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationMaintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal
2760 ORIGINAL CONTRIBUTIONS nature publishing group 10.1038/ajg.2009.410 Maintenance Treatment With Azathioprine in Ulcerative Colitis: Outcome and Predictive Factors After Drug Withdrawal Andrea Cassinotti,
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationDoncaster & Bassetlaw Medicines Formulary
Doncaster & Bassetlaw Medicines Formulary Section 1.5 Chronic Bowel Disorders (including IBD) Aminosalicylates: Mesalazine 400mg and 800mg MR Tablets (Octasa) Mesalazine 1.2g MR Tablets (Mezavant XL) Mesalazine
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationThe thiopurines azathioprine (AZA) and 6-mercaptopurine
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:1195 1201 Timing of Myelosuppression During Thiopurine Therapy for Inflammatory Bowel Disease: Implications for Monitoring Recommendations JAMES D. LEWIS,*,,
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationEDUCATION PRACTICE. Initiating Azathioprine for Crohn s Disease. The Problem. Clinical Scenario. Management Strategies Education
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:460 465 EDUCATION PRACTICE Initiating Azathioprine for Crohn s Disease BARRETT G. LEVESQUE* and EDWARD V. LOFTUS JR *Scripps Clinic, Division of Gastroenterology,
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationavailable at
Journal of Crohn's and Colitis (2009) 3, 32 37 available at www.sciencedirect.com An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from
More informationIncidence of Neoplasms in Patients Who Develop Sustained Leukopenia During or After Treatment With 6-Mercaptopurine for Inflammatory Bowel Disease
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2006;4:1025 1029 Incidence of Neoplasms in Patients Who Develop Sustained Leukopenia During or After Treatment With 6-Mercaptopurine for Inflammatory Bowel Disease
More information5-aminosalicylic acid (5-ASA) is the mainstay of first-line therapy
MMX Mesalamine for Induction and Maintenance Therapy in Mild-to-Moderate Ulcerative Colitis Stephen B. Hanauer, MD 1 ; Gary R. Lichtenstein, MD 2 ; Michael A. Kamm, MD 3 ; William J. Sandborn, MD 4 ; Kirstin
More informationClinical Use and Practical Application of TPMT Enzyme and 6-Mercaptopurine Metabolite Monitoring in IBD Ernest G. Seidman, MD
GENETIC TESTING FOR IBD Clinical Use and Practical Application of TPMT Enzyme and 6-Mercaptopurine Metabolite Monitoring in IBD Ernest G. Seidman, MD Division of Gastroenterology, Hepatology, and Nutrition,
More informationOptimizing the Medical Management of IBD by Primary Care Clinicians
Optimizing the Medical Management of IBD by Primary Care Clinicians 1. Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR. Corticosteroids and immunomodulators: postoperative infectious
More informationUlcerative colitis (UC) is a chronic disease that is commonly
ORIGINAL ARTICLE Voting with Their Feet (VWF) Endpoint: A Meta-Analysis of an Alternative Endpoint in Clinical Trials, Using 5-ASA Induction Studies in Ulcerative Colitis Sujal C. Rangwalla, DO,* Akbar
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationEfficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease
Online Submissions: wjg.wjgnet.com World J Gastroenterol 2008 July 21; 14(27): 4342-4346 wjg@wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 doi:10.3748/wjg.14.4342 2008 The WJG Press. All
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationIBD Case Studies. David Rowbotham. Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital
IBD Case Studies David Rowbotham Clinical Director & Consultant Gastroenterologist Dept of Gastroenterology & Hepatology Auckland City Hospital Dr David Rowbotham The Leeds Teaching Hospitals NHS Trust
More informationFERRING PHARMACEUTICALS. Enjoy The simple COR/939/2014/CH3
Enjoy The simple pleasures of life COR/939/2014/CH3 Ulcerative colitis disrupts the simple pleasures in life Patients with ulcerative colitis may live with a considerable symptom burden despite medical
More informationMucosal healing: does it really matter?
Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does it really matter? Professor Jean-Frédéric Colombel, New York, USA Oxford Inflammatory Bowel Disease MasterClass Mucosal healing: does
More informationDefinitions. Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency)
CROHN S DISEASE Definitions Clinical remission: Resolution of symptoms (stool frequency 3/day, no bleeding and no urgency) Recurrence: The reappearance of lesions after surgical resection Endoscopic remission:
More informationPatient selection for azathioprine - typical courses of Crohn s disease
Patient selection for azathioprine - typical courses of Crohn s disease remitting 44% steroid refractory 20% remitting 48% steroid refractory 21% 36% steroid dependent 31% steroid dependent Munkholm et
More informationJohn F. Valentine, MD Inflammatory Bowel Disease Program University of Utah
John F. Valentine, MD Inflammatory Bowel Disease Program University of Utah Hawaii 1/20/2017 DISCLOSURES Research Support: NIH, Pfizer, Celgene, AbbVie, Roche/Genentech, Takeda, CCFA OBJECTIVES Review
More information5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease
5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease David T. Rubin, MD Associate Professor of Medicine Co-Director, Inflammatory Bowel Disease Center University it of Chicago Medical
More informationReview article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease
Aliment Pharmacol Ther 23; 18 (Suppl. 2): 1 5. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease P. MUNKHOLM Department of Medical Gastroenterology, Hvidovre
More informationLeucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide
656 Division of Gastroenterology, Division of Clinical Pharmacology, Department of Pharmacology, and Section of Biostatistics, Mayo Clinic, Rochester, MN, USA PWLowry C L Franklin ALWeaver C L Szumlanski
More informationC olorectal cancer (CRC) is one of the most feared
1573 INFLAMMATORY BOWEL DISEASE 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study T P van Staa, T Card, R F Logan, H G M Leufkens... See end
More informationOutcomes of immunosuppressors and biologic drugs in inflammatory bowel diseases: a real life experience
Outcomes of immunosuppressors and biologic drugs in inflammatory bowel Treatments and therapeutic approaches in IBD are constantly evolving. The newly emerged biologic treatments are one such evolving
More informationCopyright 2014 The Authors This work is made available under the Creative Commons Attribution 3.0 License (CC BY 3.0)
s Kennedy, N.A. et al. (2014) Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients. Alimentary Pharmacology
More informationInflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and network meta-analysis
Wheat et al. BMC Gastroenterology (2017) 17:52 DOI 10.1186/s12876-017-0602-0 RESEARCH ARTICLE Inflammatory Bowel Disease (IBD) pharmacotherapy and the risk of serious infection: a systematic review and
More informationDeterminants of Topical 5-Aminosalicylic Acid Use in Veterans with Ulcerative Colitis
Research Article imedpub Journals http://www.imedpub.com/ Abstract Determinants of Topical 5-Aminosalicylic Acid Use in Veterans with Ulcerative Colitis Aims: The aim of our study was to identify the determinants
More informationCHAPTER 9. Efficacy of Thioguanine Treatment in Inflammatory Bowel disease: a Systematic Review
CHAPTER 9 Efficacy of Thioguanine Treatment in Inflammatory Bowel disease: a Systematic Review Berrie Meijer 1 Chris JJ Mulder 1 Godefridus J Peters 2 Adriaan A van Bodegraven 1,3 Nanne KH de Boer 1 8
More informationInflammatory Bowel Disease Drug Therapy 2016
Inflammatory Bowel Disease Drug Therapy 206 David T. Rubin, MD, FACG Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Objectives Outline the goals of
More informationArticle: Min, T and Ford, AC (2016) Efficacy of mesalazine in IBS. Gut, 65 (1). pp ISSN
This is a repository copy of Efficacy of mesalazine in IBS. White Rose Research Online URL for this paper: http://eprints.whiterose.ac.uk/97338/ Version: Accepted Version Article: Min, T and Ford, AC (2016)
More informationClinical Trials in IBD. Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases
Clinical Trials in IBD Bruce Yacyshyn MD Professor of Medicine Division of Digestive Diseases Objectives Today s discussion will address the following topics: Similarities and differences between Crohn
More informationReview Article Immunomodulators and Immunosuppressants for Japanese Patients with Ulcerative Colitis
International Scholarly Research Network ISRN Gastroenterology Volume 2011, Article ID 194324, 5 pages doi:10.5402/2011/194324 Review Article Immunomodulators and Immunosuppressants for Japanese Patients
More informationInhibition of Human Thiopurine S-Methyltransferase (TPMT) by. Various NSAIDs in vitro: a Mechanism for Possible Drug. Interactions
DMD This Fast article Forward. has not been Published copyedited and on formatted. June 7, The 2007 final as version doi:10.1124/dmd.107.016287 may differ from this version. Inhibition of Human Thiopurine
More informationEffect of Combination Therapy of Allopurinol and Reduced Dose of Azathioprine on Inflammatory Bowel Disease (IBD)
J. Basic. Appl. Sci. Res., 3(7)820-825, 2013 2013, TextRoad Publication ISSN 2090-4304 Journal of Basic and Applied Scientific Research www.textroad.com Effect of Combination Therapy of Allopurinol and
More informationCHAPTER 5. How I Treat my Inflammatory Bowel Disease-Patients with Thiopurines? 1 Department of Gastroenterology and Hepatology,
CHAPTER 5 How I Treat my Inflammatory Bowel Disease-Patients with Thiopurines? 4 Berrie Meijer 1 Chris JJ Mulder 1 Adriaan A van Bodegraven 1,2 Nanne KH de Boer 1 1 Department of Gastroenterology and Hepatology,
More informationTopical therapy is underused in patients with ulcerative colitis
Journal of Crohn's and Colitis (2014) 8, 56 63 Available online at www.sciencedirect.com ScienceDirect Topical therapy is underused in patients with ulcerative colitis F. Seibold a, f,, N. Fournier b,
More informationCommunicating with the IBD Patient: How to convey risks and benefits
Communicating with the IBD Patient: How to convey risks and benefits October 30, 2011 ACG Postgraduate Course National Harbor, Maryland Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationImpact of endoscopic monitoring in postoperative Crohn s disease patients already receiving pharmacological prevention of recurrence
1130-0108/2015/107/10/586-590 Revista Española de Enfermedades Digestivas Copyright 2015 Arán Ediciones, S. L. Rev Esp Enferm Dig (Madrid Vol. 107, N.º 10, pp. 586-590, 2015 ORIGINAL PAPERS Impact of endoscopic
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationINFLAMMATORY BOWEL DISEASE
1. Medical Condition INFLAMMATORY BOWEL DISEASE (IBD) specifically includes Crohn s disease (CD) and ulcerative colitis (UC) but also includes IBD unclassified (IBDu), seen in about 10% of cases. These
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationTREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS
TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS Target Audience: Physicians, Physician Assistants, Nurse Practitioners and Nurses impacted by the protocol. Scope/Patient Population: All adult
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationReview article: remission rates achievable by current therapies for inflammatory bowel disease
Alimentary Pharmacology and Therapeutics Review article: remission rates achievable by current therapies for inflammatory bowel disease L. Peyrin-Biroulet* & M. Lémann,1 *Inserm U954 and Department of
More informationEfficacy and Safety of Long-Term Thiopurine Maintenance Treatment in Japanese Patients With Ulcerative Colitis
ORIGINAL ARTICLE ISSN 1598-9100(Print) ISSN 2288-1956(Online) http://dx.doi.org/10.5217/ir.2015.13.3.250 Intest Res 2015;13(3):250-258 Efficacy and Safety of Long-Term Thiopurine Maintenance Treatment
More informationPredicting the natural history of IBD. Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium
Predicting the natural history of IBD Séverine Vermeire, MD, PhD Department of Gastroenterology University Hospital Leuven Belgium Patient 1 Patient 2 Age 22 Frequent cramps and diarrhea for 6 months Weight
More informationOxford Inflammatory Bowel Disease MasterClass The mesalazine chamaeleon
Oxford Inflammatory Bowel Disease MasterClass The mesalazine chamaeleon Ailsa Hart Lead IBD Unit, St Mark s Hospital Senior Clinical lecturer Imperial College, London Oxford Inflammatory Bowel Disease
More informationTreatment of Inflammatory Bowel Disease. Michael Weiss MD, FACG
Treatment of Inflammatory Bowel Disease Michael Weiss MD, FACG What is IBD? IBD is an immune-mediated chronic intestinal disorder, characterized by chronic or relapsing inflammation within the GI tract.
More informationMonth/Year of Review: September 2012 Date of Last Review: September 2010
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationTREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS
TREATMENT OF INPATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS Target Audience: Physicians, Physician Assistants, Nurse Practitioners and Nurses impacted by the protocol. Scope/Patient Population: All adult
More information5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA
5-ASA for the treatment of Crohn s disease DR. STEPHEN HANAUER FEINBERG SCHOOL OF MEDICINE, NORTHWESTERN UNIVERSITY, CHICAGO, IL, USA Background RCTs investigating the efficacy of aminosalicylates for
More informationAzathioprine (AZA), and its active metabolite 6-mercaptopurine,
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2009;7:80 85 Azathioprine Withdrawal in Patients With Crohn s Disease Maintained on Prolonged Remission: A High Risk of Relapse XAVIER TRETON,* YORAM BOUHNIK,*
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationInfliximab (Remicade) for paediatric ulcerative colitis - second line
Infliximab (Remicade) for paediatric ulcerative colitis - second line September 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationCrohn s disease is a chronic, progressive, destructive
Mini-Reviews and Perspectives Current Directions in IBD Therapy: What Goals Are Feasible With Biological Modifiers? WILLIAM J. SANDBORN Inflammatory Bowel Disease Clinic, Division of Gastroenterology and
More informationPersonalized Medicine in IBD
Personalized Medicine in IBD Anita Afzali MD, MPH Assistant Professor of Medicine Director, Inflammatory Bowel Diseases Program University of Washington Harborview Medical Center CCFA April 2 nd, 2016
More information